A new clinical trial is exploring SA53-OS, an MDM2 inhibitor, for people with advanced solid tumors, including #dedifferentiated #liposarcoma (#DDLPS). Learn more about this study, who may be eligible, and how the treatment is given.
clinicaltrials.gov/study/NCT065...
#ClinicalTrials #MDM2

The STC-15 (a METTL3 inhibitor) Phase 2 monotherapy trial is currently recruiting for #DDLPS patients. Learn more: clinicaltrials.gov/study/NCT069... #Liposarcoma #Sarcoma #RareCancer #METTL3Sinhibitor

New publication from experts examines the #BRIGHTLINE-1 trial and the potential of #brigimadlin for people with dedifferentiated #liposarcoma. Read more: bit.ly/BrigimadlinU... #DDLPS #SarcomaResearch #SaveBrigimadlin #PatientVoices @boehringerglobal.bsky.social